Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy by Kopylov, Uri et al.
Aliment Pharmacol Ther. 2020;52:135–142. wileyonlinelibrary.com/journal/apt   |  135© 2020 John Wiley & Sons Ltd
 
Received: 24 February 2020  |  First decision: 26 March 2020  |  Accepted: 19 April 2020
DOI: 10.1111/apt.15784  
Effectiveness of ustekinumab dose escalation in Crohn’s 
disease patients with insufficient response to standard-dose 
subcutaneous maintenance therapy
Uri Kopylov1  |   Jurij Hanzel3 |   Claire Liefferinckx4 |   Davide De Marco2 |   
Nicola Imperatore5  |   Nikolas Plevris6  |   Iria Baston-Rey7 |   Richard J. Harris8 |   
Marie Truyens9 |   Viktor Domislovic10 |   Stephan Vavricka11 |   Vince Biemans12,13  |   
Sally Myers14 |   Shaji Sebastian14  |   Shomron Ben-Horin1 |   Yago González Lama15 |   
Cyrielle Gilletta16 |   Bar-Gil Shitrit Ariella17 |   Zuzana Zelinkova18 |   Roni Weisshof19 |   
Darragh Storan20 |   Eran Zittan21  |   Klaudia Farkas22 |   Tamas Molnar22 |   
Denis Franchimont4 |   Anneline Cremer4 |   Waqqas Afif2 |   Fabiana Castiglione5 |   
Charles Lees6 |   Manuel Barreiro-de Acosta7 |   Triana Lobaton9 |   Glen Doherty20 |   
Zeljko Krznaric19 |   Marieke Pierik12 |   Frank Hoentjen13 |   David Drobne3
The Handling Editor for this article was Professor Roy Pounder, and it was accepted for publication after full peer-review. 
All authors of this study are the members of the Ustekinumab escalation study group. 
1 Tel Aviv, Israel
2 Montreal, Canada
3 Ljubljana, Slovenia
4 Brussels, Belgium
5 Naples, Italy
6 Edinburgh, UK
7 Santiago de Compostela, Spain
8 Southampton, UK
9 Ghent, Belgium
10 Zagreb, Croatia
11 Zurich, Switzerland
12 Maastricht, The Netherlands
13 Nijmegen, The Netherlands
14 Hull, UK
15 Madrid, Spain
16 Toulouse, France
17 Jerusalem, Israel
18 Bratislava, Slovakia
19 Haifa, Israel
20 Dublin, Ireland
21 Afula, Israel
22 Szeged, Hungary
Correspondence
Uri Kopylov, Department of 
Gastroenterology, Sheba Medical Center, 
Summary
Background: Ustekinumab is effective in Crohn's disease. However, a substantial pro-
portion of patients will not respond or lose response to ustekinumab. The current 
evidence to support the effectiveness of dose-optimisation for ustekinumab nonre-
sponse is limited.
Aim: To assess the effectiveness of dose escalation of ustekinumab.
Methods: This was a multicentre retrospective cohort study. We included active 
Crohn's disease patients who received a standard-dose intravenous induction and at 
least one subcutaneous ustekinumab 90 mg dose. All enrolled patients received dose 
escalation by either shortening the interval between the doses to every 4 or 6 weeks, 
intravenous reinduction or a combination of strategies. The primary outcome of the 
study was clinical response at week 16 after dose escalation.
Results: A total of 142 patients (22 centres/14 countries) were included. The patients 
were dose-escalated after a median treatment duration of 30 weeks. At week 16 from 
escalation, 73/142 (51.4%) responded to treatment, including 55/142 (38.7%) in clini-
cal remission. Corticosteroid-free remission was achieved in 6/34 (17.6%) patients on 
corticosteroids at the time of escalation; 118/142 (83%) continued treatment beyond 
week 16. Follow-up data beyond week 16 were available for 74/118 (62.7%) patients. 
On the last follow-up, 51/98 (52%) patients with available data responded to treat-
ment, including 41/98 (42%) in clinical remission.
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1  | INTRODUC TION
Ustekinumab (UST) is a monoclonal antibody that targets the p40 
subunit of interleukin (IL) 12 and 23. UST is effective for treatment 
of Crohn's disease (CD) and ulcerative colitis.1-4 In addition to ran-
domised controlled trials, multiple real-world studies corroborated 
the effectiveness of UST in the treatment of CD.5-19 However, the 
risk of primary and secondary loss of response to UST has not been 
extensively reported. In the recently published long-term extension 
of the UNITI trials, clinical remission was well maintained from week 
44 to 92 for both every 12 weeks (q12w) (77.4%/72.6%) and every 
8 weeks (q8w) regimen (84.1%/74.4%).3 Nevertheless, the rates of 
sustained response appear to be lower in the real-world setting. In a 
multicentre real-world study from the Netherlands, the probability 
of remaining on ustekinumab treatment at 52 weeks was 62.9%.7 
Similar results were reported in a recent Belgian cohort study.13
The vast majority of CD patients treated with ustekinumab in 
the real-world setting have failed at least two previous biologics.9 
Additional therapeutic options in these patients are severely limited. 
Therefore, there is a need for an effective strategy for management 
of nonresponse to ustekinumab.
The standard ustekinumab treatment regimen for CD includes an 
intravenous (IV) induction (adjusted 6 mg/kg dose) followed by UST sub-
cutaneous (SC) 90 mg administered every 12 or 8 weeks. No significant 
differences between both dose regimens with regards to clinical effi-
cacy were demonstrated in the UNITI trials.2,3 However, every 8 weeks 
regimen (q8w) was more effective in achieving endoscopic response.1 
Dose escalation q8w in patients failing to respond to q12w regimen has 
been shown to be effective.3,20 Yet, there are scarce data to support 
efficacy of further dose escalation in patients failing q8w dosing. In a 
Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube 
Digestif (GETAID) cohort study, published as a conference report, clinical 
response was obtained in 43/69 (57.1%) of the patients after 2.1 months 
post every 4 weeks (q4w) optimisation.21 In addition, successful intrave-
nous reinduction was described in a case series of three patients with 
either primary or secondary nonresponse to UST.22
Additional data to support a dose-escalation regimen in CD pa-
tients failing to respond to ustekinumab are required. The aim of the 
present study was to evaluate the effectiveness and safety of dose 
escalation of UST in patients who did not respond or lost response 
to ustekinumab q8w maintenance dose.
2  | METHODS
This was a multicentre retrospective cohort study. The protocol was 
reviewed and approved by the Clinical committee of the European 
Crohn's and Colitis organisation (ECCO).The cohort study included 
active (defined as Harvey-Bradshaw Index (HBI) ≥5 or Crohn's dis-
ease activity index (CDAI) ≥150) CD patients. The included patients 
received at least two doses of ustekinumab (IV induction of 6 mg/kg 
followed by SC 90 mg injection) and were either dose-escalated to 
q4w or q6w or, alternatively, received an IV reinduction (6 mg/kg) in-
stead of a scheduled SC dose or a combination of IV and SC escalation. 
Patients without active disease as per CDAI/HBI, and patients with 
pouch or ostomy were excluded from the study. Patients who started 
q12w maintenance after IV induction could be included in the study 
only if they were escalated to q8w regimen prior to further escalation.
The primary objective of the study was clinical response (ΔHBI ≥ 3 
or ΔCDAI ≥ 70) at week 16 from the escalation. Secondary outcomes in-
cluded clinical remission (HBI ≤ 4; CDAI ≤ 150) at week 16; C-reactive 
protein (CRP) normalisation (as per cut-off levels used in the correspond-
ing institutions) at week 16 (in patients with elevated CRP at the time of 
escalation); steroid-free clinical remission at week 16 (in patients receiving 
systemic corticosteroids at the time of escalation) and steroid-free clini-
cal response at week 16. In addition to week 16 from the escalation, we 
addressed long-term outcomes (last visit after week 16, up to 52 weeks 
from dose escalation) when available. Last follow-up secondary outcomes 
included clinical response and remission, steroid-free response and remis-
sion, improvement in perianal fistula drainage or fistula healing (based on 
physician's assessment or per imaging where available). We also collected 
safety outcomes including patient-reported adverse events, serious ad-
verse events (resulting in hospitalisation or treatment discontinuation), 
hospitalisations and CD-related surgery following dose escalation.
3  | STATISTIC AL METHODS
Descriptive statistics were presented as means ± standard deviations 
(SD) for parametric variables, medians with interquartile ranges (IQR) 
for nonparametric continuous variables and percentages for cate-
gorical variables. Categorical variables were analysed by chi-square/
Fisher's exact test and continuous variables by t test/Mann Whitney 
test as appropriate. A two-tailed P < 0.05 was considered statistically 
significant. We constructed a multivariate logistic regression model to 
identify the independent predictors of ustekinumab discontinuation 
at week 52. Variables with significance level < 0.1 on the univariate 
analysis were included in the model. To investigate the effect of the 
variables on duration of continued UST treatment, we performed a 
survival analysis, Kaplan-Meier survival curve and Cox multivariate 
proportional hazard model. The model included variables with sig-
nificance level < 0.1 on univariate analysis. We used IBM SPSS sta-
tistic (Version 20.0) in performing the analysis. Ethical approval was 
obtained as per the requirements of each of the participating centres.
Ramat-Gan and Sackler Medical School, Tel 
Aviv University, Israel.
Email: ukopylov@gmail.com
Conclusions: Intensification of ustekinumab maintenance dosage was effective in 
over 50% of the patients. This strategy should be considered in patients who are 
nonresponsive to every 8 weeks ustekinumab maintenance dosing.
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4  | RESULTS
One hundred and forty-two patients from 22 centres in 14 countries 
(13 Europe and 1 Canada) were included in the study. The clinical and 
demographic characteristics of the patients are detailed in Table 1. 
Only 3.5% of the patients were biologic-naive, 23.2% received one 
prior biologic, 39.4% received two prior biologics, 32.4% received 
three prior biologics and 1.4% received four prior biologics. Fifty-
seven (40%) of the patients had previously received both anti-TNFs 
and vedolizumab. One hundred and six (77%) had elevated CRP at 
dose escalation. All patients received intravenous UST induction 
and SC maintenance (90 mg SC q8w); 9/142 (6.3%) received q12w 
and were escalated to q8w before inclusion in the study. The mean 
duration of SC maintenance therapy before dose escalation was 29 
(IQR 18-46) weeks with a median of four (IQR 2-6) injections. All pa-
tients had active CD (median HBI- 8 (IQR 6-12) at the time of dose 
escalation.
Ninety-one (64.1%) of the patients were escalated to q4w regi-
men, 20/142 (14.1%) patients were escalated to q6w, 14/142 (9.9%) 
patients received an IV reinduction and 17/142 (12%) a combination 
of IV reinduction and interval shortening.
5  | TRE ATMENT OUTCOMES
5.1 | Week 16 from escalation
Clinical response was achieved by 73/142 (51.4%) patients, includ-
ing 55/142 (38.7%) patients in clinical remission. CRP normalised 
in 21/98 (21.4%) patients with CRP values available at both time 
points. Systemic corticosteroids were discontinued in 23/34 (67.6%) 
patients who were on corticosteroids at the time of escalation. 
Corticosteroid-free remission was achieved by 6/34(17.6%) patients 
on corticosteroids upon escalation. Corticosteroid treatment was 
started by 6/108 (5.6%) patients who were not treated with corti-
costeroids upon dose escalation.
The likelihood of achieving clinical remission was similar be-
tween patients who received intravenous reinduction vs those who 
received SC interval shortening (Table 2). None of the clinical or de-
mographic parameters were associated with likelihood of response 
(Table 2). Ustekinumab was discontinued by 24 (17%) of the patients 
due to clinical nonresponse (17/91 (18.7%) patients who escalated 
to q4w, 1/20 (5%) patients escalated to q6w, 5/14 (35.6%) patients 
who received IV reinduction and 1/17(5.9%) patients who received 
both IV reinduction and SC escalation respectively).
5.2 | Maintenance
Clinical follow-up beyond week 16 was available for 74/118 
(62.7%) patients who continued treatment (median duration 
of follow-up was 26 (IQR 32-52) weeks); 44 patients did not 
have follow-up data available beyond week 16. Maintenance 
outcomes were reported for patients who had available data 
beyond week 16 or discontinued treatment by week 16 (n = 98) 
(Figures 1 and 2) . At last follow-up, 51/98 (52%) patients re-
sponded to treatment, including 41/98 (42%) who achieved 
clinical remission (with the exclusion of patients who discontin-
ued ustekinumab by week 16, 51/74 (68.9%) responded includ-
ing 41/74 (55.4%) who achieved clinical remission). Eleven of 
53 (20.7%) patients who did not respond at week 16 and had 
available maintenance data responded subsequently, including 
9/54 (17%) who achieved clinical remission. Corticosteroid-free 
remission was achieved by 9/34 (26.5%) patients who were 
treated with corticosteroids at dose escalation (including six 
patients who had achieved corticosteroid-free remission by 
week 16 as described above). Corticosteroids were initiated 
in two additional patients after week 16; overall, 8/108 (7.4%) 
TA B L E  1   Clinical and demographic characteristics of the 
included patients
Age at treatment onset, years (median, interquartile 
range) 35 (26-49)
Disease duration (median, interquartile range) 10 (5-17)
Gender (n, %)
Male 55 (38.7%)
Female 87 (61.3%)
Behaviour (n, %)
Nonstricturing nonpenetrating 51 (35.9%)
Stricturing 53 (37.3%)
Penetrating 38 (26.8%)
Smoking (n, %)
Never 101 (70.9%)
Active smoker 20 (14.2%)
Past smoker 21 (14.9%)
CD location (n, %)
Small bowel 25 (17.6%)
Colon 31 (21.8%)
Small bowel and colon 86 (60.6%)
History of perianal disease (n, %) 56 (40.1%)
History of previous abdominal surgery (n, %) 81 (57%)
Active perianal disease at escalation (n, %) 33 (23.2%)
Number of previous biologic therapies (n, %)
Previous biologics (n, %)
None 5 (3.5%)
1 33 (23.2%)
2 56 (39.4%)
3 46 (32.4%)
4 2 (1.4%)
Elevated CRP (n, %) 106 (77.4%)
Systemic corticosteroids at escalation (n, %) 34 (24%)
Concomitant immunomodulators at escalation (n, %) 24 (16.9)
Abbreviations: CD, Crohn's disease; CRP, C-reactive protein.
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patients who were not on corticosteroids upon dose escalation 
were started on corticosteroids throughout the duration of the 
follow-up. Sixty-seven (68.4%) patients continued ustekinumab 
treatment at last follow-up.
Kaplan-Meier curve for discontinuation-free survival appears 
on Figure 3. None of the clinical or demographic parameters, 
including the escalation strategy, was significantly associated 
with the duration of drug discontinuation-free survival (data not 
shown).
Endoscopic evaluation both before (within 4 weeks) escalation 
and after escalation (24 (IQR 16-32) weeks from escalation) was 
available for 23 patients. Mucosal healing was reported for 2/23 
(8.6%) patients. An endoscopic improvement was reported for 11 
(47.8%) of 23 patients and no improvement for 10 (43.4%) of 23 
patients.
Of 33 patients with active perianal disease, improvement was 
reported by 14 (42.4%) patients at week 16. Out of 17 patients with 
active perianal disease (and available data) beyond week 16, im-
provement was reported by 11 (64.7%) patients.
6  | SAFET Y
Adverse events followed escalation were reported by 11 (7.7%) 
of the 142 patient and included skin eruptions (two patients), 
upper respiratory tract infection that required hospitalisation 
and subsequent treatment discontinuation (one patient), acute 
gastroenteritis of unknown aetiology (two patients), clostridium 
difficile infection (one patient), CMV colitis (one patient), concen-
tration disturbance (one patient), benign breast lump (one patient), 
cervical intraepithelial neoplasia grade 1 (one patient) and non-
melanoma skin cancer (one patient). Ten (7%) patients required 
CD-related surgery (nine bowel resection and one perianal ab-
scess drainage).
 
Week 16 response
P
no (n = 69) yes (n = 73)
n % n %
Age at treatment onset, years (median 
interquartile range)
34 (25-44) 37 (27-50) 0.25
Gender (n, %)
Male 22 31.9% 33 45.2% 0.1
Female 47 68.1% 40 54.8%
CD location (n, %)
Small bowel 12 17.4% 13 17.8% 0.99
Colon 15 21.7% 16 21.9%
Small bowel and colon 42 60.9% 44 60.3%
Behaviour (n, %)
Nonstricturing nonpenetrating 24 34.8% 27 37.0% 0.2
Stricturing 22 31.9% 31 42.5%
Penetrating 23 33.3% 15 20.5%
Smoking (n, %)
Never 51 75.0% 49 67.1% 0.5
Active smoker 9 13.2% 11 15.1%  
Type of escalation
Past smoker 8 11.8% 13 17.8%  
Q4w 43 62.3% 48 65.8% 0.48
Q4w + IV reinduction 6 8.7% 10 13.7%
Q6w 11 15.9% 10 13.7%
IV reinduction 9 13.0% 5 6.8%
Elevated CRP (n, %) 56 82.1% 52 72.9% 0.2
Systemic corticosteroids at escalation 
(n, %)
20 29.0% 15 20.5% 0.7
Concomitant immunomodulators at 
escalation (n, %)
12 17.4% 12 16.4% 0.9
Abbreviations: CD, Crohn's disease; CRP, C-reactive protein; IV, intravenous; Q4w- every 4 weeks; 
Q6w, every 6 weeks.
TA B L E  2   Variables associated with 
week 16 response
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7  | DISCUSSION
The results of our study suggest that CD patients who are nonre-
sponsive to standard maintenance dosing of ustekinumab may ben-
efit from dose escalation. Dose escalation was effective in about 
50% of the patients, with most of the responders achieving clinical 
remission.
Primary and secondary nonresponse and treatment discontinu-
ation are frequent for all treatments in IBD, including ustekinumab, 
with rates of treatment discontinuation approaching 40%.7,13 These 
high rates of nonresponse are not surprising considering the refrac-
toriness of the patients included in the real-life cohorts published 
so far.9
To date, the strategy for management of loss of response to 
UST has not been clearly established. While for patients treated 
with tumour necrosis factor (TNF)-alpha inhibitors, therapeutic 
drug monitoring may provide important guidance for selection of 
strategy.23-26 The correlation of ustekinumab levels with treatment 
outcomes is not as robust.6,12,27 Thus, the escalation strategy is cur-
rently empiric and nonstandardised.
Even though in the original UNITI 1/UNITI 2 trial no significant dif-
ference in the efficacy of both maintenance regimens was detected,2 
the endoscopic response was more frequent in the q8w maintenance 
arm.1 In the long-term extension study of UNITI, patients who re-
quired dose-adjustment from q12w to q8w regimen were less likely to 
remain in clinical remission throughout the duration of follow-up.3,20 
However, only a few of the recent real-world studies included a signif-
icant proportion of patients who had received the currently approved 
intravenous induction regimen followed by a standard q12w or q8w 
maintenance,7,13,14 as most of these studies were published before the 
regulatory approval of intravenous ustekinumab for Crohn's disease. 
The effectiveness of further dose escalation in patients who did not re-
spond to q8w dosing has not been reported so far, with the exception 
of the GETAID experience reported as an abstract (57% response in 69 
patients after a median of 2.1 months)21 and a very limited number of 
patients in early real-world series.12,16 In addition to interval shorten-
ing, a strategy of intravenous reinduction is utilised in some centres; 
however, the evidence to support it is minimal to date.28
Our study has some limitations. Primarily, this was a multicentre 
retrospective study that shares common limitations with similar 
efforts, namely heterogeneity in treatment strategies, lack of pre-
defined timing of visits and missing biological data. Endoscopic 
response was not systematically evaluated, and perianal disease 
reporting was subjective and not universally available. Moreover, 
in many patients, the escalation was attempted relatively early on, 
and it is possible that some of the patients could have gradually 
improved with standard management strategy. As mentioned, the 
current study was descriptive and did not allow us to compare the 
effectiveness of the escalation to continuation of standard mainte-
nance dosing. Our patients were all included by university-affiliated 
tertiary centres; nonetheless, it is possible that additional visits to 
community physicians could have occurred, leading to potentially 
missing prescription data or dose changes. Finally, we could not 
F I G U R E  1   Patient inclusion chart. UST-ustekinumab
Patients included for 
week 16 outcomes 
(n = 142)
Stopped UST at 
week 16 
(n = 24)
Continued UST 
(n = 118)
Follow-up data 
available
(n = 74)
No follow-up data 
beyond week 16
(n = 44)
Included for 
maintenance 
outcomes (n = 98)
F I G U R E  2   Clinical outcomes at week 
16 of ustekinumab escalation and last 
follow-up
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detect differences in efficacy between the escalation strategies, al-
beit the study was not powered to detect such difference.
On the other hand, this study applied stringent inclusion criteria 
and clear treatment outcomes (only patients with available clinical 
scores were included). In addition, this was a large multinational and 
multicentre report that maximised the amount of the available data 
for analysis and reflected real-life practices of IBD specialists across 
the ECCO community. Finally, our study did not reveal any new 
safety concerns; however, a retrospective study is not designed to 
capture mild adverse events that could have resolved without being 
reported to the IBD specialist.
In summary, the data accumulated in our study support the ef-
ficacy of dose escalation in CD patients who do not respond or lost 
response to q8w maintenance regimen. Our results merit validation 
in future prospective studies.
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